# SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

> **NCT05752461** · PHASE2 · COMPLETED · sponsor: **Beijing Suncadia Pharmaceuticals Co., Ltd** · enrollment: 353 (actual)

## Conditions studied

- Prevention of Venous Thromboembolism After Knee Arthroplasty

## Interventions

- **DRUG:** SHR-2004 injection
- **DRUG:** SHR-2004 injection
- **DRUG:** SHR-2004 injection
- **DRUG:** Enoxaparin sodium injection

## Key facts

- **NCT ID:** NCT05752461
- **Lead sponsor:** Beijing Suncadia Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-12
- **Primary completion:** 2024-04-12
- **Final completion:** 2024-06-25
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05752461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05752461, "SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05752461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*